

09/907 900

Hit Count Set Name
result setSet Name Query
side by side

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L11 l2 with L10740 L11L10 recombinase or transposase or transposition of transposed or integrase
or lox! or cre! or frt! or att! or loxp! or loxp511 or attb! or attp! or attl!
or attr!16528 L10L9 l1 with L82492 L9L8 pcr! or lcr! or amplification or amplifies or amplified or amplify456951 L8L7 l1 and l4247 L7L6 l3 and l43 L6L5 l1 with l2 with L40 L5L4 does not recombine26475 L4L3 l1 with l22493 L3L2 pcr or amplification or amplified or amplify or amplifies or lcr457008 L2L1 recombinase or recombination or transposase or transposition or
transposed or integrase63961 L1

END OF SEARCH HISTORY

WEST**Print Selection****[Help] [Clear] [Cancel] [Print] [Print First Page]**

Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database
<input checked="" type="checkbox"/>	6143530	all	all	32	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5851808	all	all	38	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5962249	all	all	19	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5888732	all	all	* 74	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5962255	all	all	* 184	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5929307	all	all	20	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5695977	all	all	13	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5583038	all	all	* 112	USPT,PGPB,JPAB,EPAB,DWPI

Note: Print requests for more than 49 pages are denoted by '*' and are in red.**Building Room Printer**

cm1 ▼ 11e14 ▼ gblptr ▼

[Main Menu]**[Logout]**

[Generate Collection](#)[Print](#)**Search Results - Record(s) 551 through 600 of 740 returned.**

551. [5962260](#). 24 Mar 97; 05 Oct 99. Recombinant production of human and bovine receptors for modified low-density lipoprotein. Sawamura; Tatsuya, et al. 435/69.1; 435/320.1 435/7.1 530/350 536/23.5. C12N015/12 C07K014/705.
552. [5962255](#). 05 Dec 94; 05 Oct 99. Methods for producing recombinant vectors. Griffiths; Andrew David, et al. 435/69.1; 435/252.3 435/252.33 435/320.1 435/91.41. C12P021/06 C12N015/00 C12N015/63 C12N001/20.
553. [5962249](#). 20 Dec 96; 05 Oct 99. Sized-based marker identification technology. Benton; Bret, et al. 435/29; 435/235.1 435/252.3 435/254.11 435/325 435/419 435/6. C12Q001/02 C12Q001/68 C12N015/09 C12N015/90.
554. [5958680](#). 07 Jun 95; 28 Sep 99. Mammalian telomerase. Villeponteau; Bryant, et al. 435/6; 435/320.1 435/366 536/24.1 536/24.5 536/25.1 536/25.2. C12Q001/68 C12N005/08 C12N015/63 C07H021/02.
555. [5955575](#). 22 Dec 97; 21 Sep 99. Antagonists of G-protein-coupled receptor. Peri; Krishna G., et al. 530/324; 530/326. A61K038/04 A61K038/16.
556. [5952482](#). 09 Jul 97; 14 Sep 99. Production of hemoglobin having a .delta.-like globin. Kumar; Ramesh, et al. 536/23.4; 435/69.6 435/69.7 536/23.5. C07H017/00 C07H021/04 C12N015/06 C12N005/00.
557. [5952186](#). 16 Apr 96; 14 Sep 99. Reagent, method, and kit for the quantitation of oxidation-reduction phenomena in proteins and peptides. Shultz; John, et al. 435/7.9; 435/113 435/4 436/120 548/126. C12Q001/00.
558. [5949287](#). 03 Apr 98; 07 Sep 99. Power amplifier. Kurusu; Hitoshi, et al. 330/277; 330/295. H03F003/16.
559. [5948667](#). 13 Nov 96; 07 Sep 99. Xylanase obtained from an anaerobic fungus. Cheng; Kuo-Joan, et al. 435/200; 435/252.3 435/254.11 435/325 536/23.2 536/24.3. C12N009/24 C12N015/56.
560. [5945506](#). 06 Jun 95; 31 Aug 99. Chemokine expressed in fetal spleen and its production. Coleman; Roger, et al. 530/324; 435/252.3 435/320.1 435/325 435/471 435/69.5 435/71.1 435/71.2 536/23.5 930/140. C07K014/52 C12N015/19 C12N015/63 C12N005/10.
561. [5945283](#). 17 Dec 96; 31 Aug 99. Methods and kits for nucleic acid analysis using fluorescence resonance energy transfer. Kwok; Pui-Yan, et al. 435/6; 436/501. C12Q001/68.
562. [5932474](#). 21 Oct 97; 03 Aug 99. Target sequences for synthetic molecules. Tsien; Roger Y., et al. 435/320.1;. C12N015/63.
563. [5932441](#). 20 Jan 98; 03 Aug 99. Vectors for differential expression. Goding; Colin Ronald, et

al. 435/69.1; 435/320.1. C12P021/02.

-
564. 5929307. 20 Dec 96; 27 Jul 99. Method for the production of hybrid plants. Hodges; Thomas K., et al. 800/303; 435/320.1 435/419 435/468 536/23.6 536/23.72 536/23.74 536/24.1 800/274 800/278 800/287 800/288 800/298. A01H005/00 A01H001/02 C12N015/82 C12N015/29.
-
565. 5929209. 20 Dec 96; 27 Jul 99. Somatostatin receptor protein. Hadcock; John Richard, et al. 530/350; 530/300 536/22.1. C07K001/00 C07K002/00 A61K038/00 C07H019/00.
-
566. 5928914. 05 Nov 96; 27 Jul 99. Methods and compositions for transforming cells. Leboulch; Philippe, et al. 435/456; 435/183 435/320.1 435/461 435/462 435/69.1 435/70.1 536/23.1. C12N015/52 C12N015/64 C12P021/02 C07H021/04.
-
567. 5928900. 18 May 94; 27 Jul 99. Bacterial exported proteins and acellular vaccines based thereon. Masure; H. Robert, et al. 435/69.3; 424/185.1 424/190.1 424/244.1 530/350. C12P021/06 A61K039/00 A61K039/02 C07K001/00.
-
568. 5925808. 19 Dec 97; 20 Jul 99. Control of plant gene expression. Oliver; Melvin John, et al. 800/298; 435/320.1 435/419 435/468 435/469 435/470 536/23.6 536/24.1 536/24.5 800/295. C12N015/00 C12N015/29 C12N015/82 A01H004/00.
-
569. 5919652. 01 Sep 95; 06 Jul 99. Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof. Pang; Shen, et al. 435/69.1; 435/320.1 435/325 435/366 536/24.1. C12P021/00 C12N015/85 C12N005/10 C07H021/04.
-
570. 5917123. 14 Mar 97; 29 Jun 99. Transgenic mice containing a nucleic acid encoding tumor necrosis factor-.alpha. under the control of a cardiac specific regulatory region. McTiernan; Charles F., et al. 800/18; 800/13 800/14 800/3 800/8 800/9. C12N005/00 G01N033/00.
-
571. 5917019. 04 Feb 98; 29 Jun 99. Altered telomere repeat binding factor 2. de Lange; Titia, et al. 530/358; 530/350. C07K014/47.
-
572. 5916804. 17 Apr 98; 29 Jun 99. Method for site-specific integration of nucleic acids and related products. Bushman; Frederic D.. 435/325; 435/243 435/320.1 435/410 536/23.4. C12N005/10 C12N001/00 C12N015/62 C12N015/63.
-
573. 5908839. 23 Aug 96; 01 Jun 99. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders. Levitt; Roy Clifford, et al. 514/182; 514/826. A61K031/56.
-
574. 5906819. 24 Jul 96; 25 May 99. Rho target protein Rho-kinase. Kaibuchi; Kozo, et al. 424/94.5; 435/194 435/4. C12N009/12 C12Q001/00 A61K038/51.
-
575. 5900782. 16 Apr 97; 04 May 99. AGC voltage correction circuit. Igarashi; Sadao, et al. 330/254; 330/256. H03F003/45.
-
576. 5889190. 07 Jun 95; 30 Mar 99. Recombinant plant viral nucleic acids. Donson; Jon, et al. 800/288; 435/235.1 435/468 435/472 435/475 435/476 435/69.1 435/69.4 435/69.52 435/69.6 435/70.1 536/23.72 536/24.1 536/24.5 800/286 800/298. A01H005/00 C12N015/40 C12N015/82 C12N015/83.

-
577. 5888732. 07 Jun 96; 30 Mar 99. Recombinational cloning using engineered recombination sites. Hartley; James L., et al. 435/6; 435/320.1 435/91.42 536/23.1 536/24.2. C12Q001/68 C12P019/34 C12N015/63 C07H021/04.
-
578. 5885809. 07 Feb 97; 23 Mar 99. Method of producing (S)-cyanohydrins. Effenberger; Franz, et al. 435/128; 435/136 435/174 435/176 435/280 558/351. C12P013/00 C07C253/06.
-
579. 5882851. 08 Aug 96; 16 Mar 99. Cytochrome P-450 monooxygenases. Koch; Birgit Maria, et al. 435/4; 435/25 435/7.1 536/22.1. C12Q001/00 C12Q001/26 G01N033/53 C07H019/00.
-
580. 5876972. 23 Sep 96; 02 Mar 99. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation. Spengler; Dietmar, et al. 435/69.1; 435/252.3 435/320.1 435/325 435/410 435/6 536/23.5. C12P021/00 C12N015/12.
-
581. 5874259. 21 Nov 97; 23 Feb 99. Conditionally amplifiable BAC vector. Szybalski; Waclaw. 435/91.1; 435/252.33 435/320.1. C12P019/34.
-
582. 5869315. 18 Dec 95; 09 Feb 99. Modified interleukin-1.bet. converting enzyme with increased stability. Talanian; Robert V., et al. 435/226; 435/184 435/219 435/23 435/41 530/351 536/23.5. C12N009/64 C12N009/99 C07K001/00 C07H021/04.
-
583. 5866785. 07 Jun 95; 02 Feb 99. Recombinant plant viral nucleic acids. Donson; Jon, et al. 800/298; 435/235.1 435/320.1 435/69.1 435/69.4 435/69.52 435/69.6 536/23.72 536/24.1 536/24.5 800/288. A01H005/00 C12N015/12 C12N015/40 C12N015/83.
-
584. 5863786. 06 Jun 95; 26 Jan 99. Nucleic acid encoding modified human tnf.alpha. (tumor necrosis factor alpha) receptor. Feldmann; Marc, et al. 435/252.3; 435/320.1 435/69.1 435/69.7 536/23.4 536/23.5. C12N005/10 C12N015/12 C12N015/62.
-
585. 5861273. 07 Jun 95; 19 Jan 99. Chromosomal expression of heterologous genes in bacterial cells. Olson; Pamela S., et al. 435/69.1; 435/252.33 435/320.1 536/23.1 536/24.1. C12P021/02 C12N001/21 C12N015/64 C12N015/70.
-
586. 5861268. 23 May 96; 19 Jan 99. Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase. Tang; Dean G., et al. 435/25; 435/183 435/4 435/975. C12Q001/26.
-
587. 5859312. 08 Jul 96; 12 Jan 99. Transgenic non-human animals having targeting endogenous lymphocyte transduction genes and cognate human transgenes. Littman; Daniel, et al. 800/9; 435/7.1 536/23.1 800/18. C12N015/00 C07H021/04 C01N033/53.
-
588. 5859183. 13 Feb 97; 12 Jan 99. Altered telomere repeat binding factor. de Lange; Titia, et al. 530/300; 530/350. C07K004/12 C07K014/435.
-
589. 5856189. 07 Jan 97; 05 Jan 99. Cell culture model for drug bioavailability. Watkins; Paul B., et al. 435/375; 435/352 435/363 435/366 435/370 435/384. C12N005/06 C12N005/08 C12N001/38.
-
590. 5854004. 25 May 94; 29 Dec 98. Process for screening substances capable of modulating a

receptor-dependent cellular signal transmission path. Czernilofsky; Armin Peter, et al. 435/7.21; 435/6 435/8. C12Q001/68 G01N033/566.

591. 5851984. 16 Aug 96; 22 Dec 98. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides. Matthews; William, et al. 514/2; 424/85.1 435/2. A61K038/18.

592. 5851811. 01 Nov 94; 22 Dec 98. Peroxidase variants with improved hydrogen peroxide stability. Welinder; Karen Gjesing, et al. 435/192; 435/471 510/374 510/392 536/23.2. C12N009/08 C12N015/09 C12N015/53.

593. 5851808. 28 Feb 97; 22 Dec 98. Rapid subcloning using site-specific recombination. Elledge; Stephen J., et al. 435/91.4; 435/320.1 435/91.41 536/23.1. C12N005/09 C12N015/63 C12N015/64 C12N015/66.

594. 5851794. 22 May 95; 22 Dec 98. Collagen binding protein as well as its preparation. Guss; Bengt, et al. 435/69.1; 435/252.3 435/252.33 435/320.1 536/23.7. C12P021/06 C12N001/20 C12N015/09 C07H021/04.

595. 5851528. 03 Jul 97; 22 Dec 98. Methods of inhibiting complement activation. Ko; Jone-Long, et al. 424/185.1; 424/192.1 514/12 530/350 530/380. A61K038/16 C07K014/46.

596. 5846782. 21 Aug 96; 08 Dec 98. Targeting adenovirus with use of constrained peptide motifs. Wickham; Thomas J., et al. 435/69.7; 530/350. C12P021/04.

597. 5846780. 04 Oct 96; 08 Dec 98. Murine RATH gene. Levinson; Douglas Adam, et al. 435/69.2; 435/320.1 435/325 536/23.1 536/23.5. C12N015/12 C12N015/85 C07H021/04.

598. 5844093. 17 Nov 95; 01 Dec 98. Anti-EGFR single-chain Fvs and anti-EGFR antibodies. Kettleborough; A. Cathrine, et al. 530/387.3; 424/133.1 424/135.1 424/143.1 435/252.3 435/320.1 435/6 435/69.1 435/7.1 435/7.2 435/7.24 530/387.7 530/388.22 530/388.8 530/388.85 530/389.7 536/23.53. C07K016/28 C07H021/04 A61K039/395 C12N015/63.

599. 5840854. 07 Oct 96; 24 Nov 98. Monoclonal antibody BR110 and uses thereof. Hellstrom; Karl Erik, et al. 530/387.7; 424/133.1 424/138.1 424/155.1 424/181.1 435/328 435/330 530/387.3 530/388.2 530/391.3 530/391.7. A61K031/395.

600. 5840562. 12 Sep 97; 24 Nov 98. DNA encoding human cysteine protease. Diep; Dinh, et al. 435/212; 435/252.33 435/254.21 435/320.1 435/325 536/23.1 536/23.2 536/23.5. C12N009/48 C07H021/04.

Generate Collection

Print

Terms	Documents
I2 with L10	740

[Previous Page](#) [Next Page](#)

09/907908
A#10

=> s recombinase? or transposase? or transposition or integrase
L1 59596 RECOMBINASE? OR TRANSPOSEASE? OR
TRANSPOSITION OR INTEGRASE

=> s lox and loxp
L2 348 LOX AND LOXP

=> s lox and loxp511
L3 10 LOX AND LOXP511

=> s loxp and loxp511
L4 18 LOXP AND LOXP511

=> s frt(5n)(mutant or mutate or mutated or mutants)
L5 40 FRT(5N)(MUTANT OR MUTATE OR MUTATED OR
MUTANTS)

=> s attP and attB
L6 648 ATT P AND ATT B

=> s attR and attB
L7 207 ATTR AND ATT B

=> s attL and attB
L8 213 ATT L AND ATT B

=> s attL and attR
L9 275 ATT L AND ATT R

=> s l2 or l3 or l4 or l5 or l6 or l7 or l8 or l9
L10 1138 L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9

=> s l1 and l10
L11 709 L1 AND L10

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 330 DUP REM L11 (379 DUPLICATES REMOVED)

=> s l12 and py<1998

1 FILES SEARCHED...

3 FILES SEARCHED...

4 FILES SEARCHED...

L13 130 L12 AND PY<1998

=> d l13 ibib abs l-130

L13 ANSWER 1 OF 130 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
ACCESSION NUMBER: 1998:47271 BIOSIS
DOCUMENT NUMBER: PREV199800047271
TITLE: A new DNA vehicle for nonviral gene delivery: Supercoiled
minicircle.
AUTHOR(S): Darquet, A.-M.; Cameron, B.; Wils, P.; Scherman, D.;
Crouzet, J. (1)
CORPORATE SOURCE: (1) UMR 133 CNRS/Rhone-Poulenc Rorer,
Cent. Recherche de
Vitry-Alfortville, 13 Quai Jules, Guesdes, 94403 Vitry sur
Seine France
SOURCE: Gene Therapy, (***Dec., 1997***) Vol. 4, No. 12, pp.
1341-1349.
ISSN: 0969-7128.
DOCUMENT TYPE: Article
LANGUAGE: English
AB Plasmids currently used for nonviral gene transfer have the disadvantage
of carrying a bacterial origin of replication and an antibiotic resistance
gene. There is, therefore, a risk of uncontrolled dissemination of the
therapeutic gene and the antibiotic resistance gene. Minicircles are new
DNA delivery vehicles which do not have such elements and are
consequently
safer as they exhibit a high level of biological containment. They are
obtained in E. coli by att site-specific recombination mediated by the
phage lambda ***integrase***. The desired eukaryotic expression
cassette bounded by the lambda ***attP*** and ***attB*** sites was
cloned on a recombinant plasmid. The expression cassette was excised in
vivo after thermoinduction of the ***integrase*** gene leading to the

formation of two supercoiled molecules: the minicircle and the starting
plasmid lacking the expression cassette. In various cell lines, purified
minicircles exhibited a two- to 10-fold higher luciferase reporter gene
activity than the unrecombined plasmid. This could be due to either the
removal of unnecessary plasmid sequences, which could affect gene
expression, or the smaller size of minicircle which may confer better
extracellular and intracellular bioavailability and result in improved
gene delivery properties.

L13 ANSWER 2 OF 130 BIOSIS COPYRIGHT 2003 BIOLOGICAL

ABSTRACTS INC.

ACCESSION NUMBER: 1997:514307 BIOSIS

DOCUMENT NUMBER: PREV199799813510

TITLE: The site-specific integration system of the temperate
Streptococcus thermophilus bacteriophage vphi-Sfi21.

AUTHOR(S): Bruttin, Anne; Foley, Sophie; Brussow, Harald (1)
CORPORATE SOURCE: (1) Nestle Res. Cent., Nestec Ltd,
Vers-chez-les-Blanc,

CH-1000 Lausanne 26 Switzerland
SOURCE: Virology, (1997) Vol. 237, No. 1, pp. 148-158.
ISSN: 0042-6822.

DOCUMENT TYPE: Article

LANGUAGE: English

AB The temperate bacteriophage vphi-Sfi21 integrates its DNA into the
chromosome of Streptococcus thermophilus strains via site-specific
recombination. Nucleotide sequencing of the attachment sites identified a
40-bp identity region which surprisingly overlaps both the 18-terminal bp
of the phage ***integrase*** gene and the 11-terminal bp of a host
tRNA-Arg gene. A 2.4-kb phage DNA segment, covering ***attP*** ,
the

phage ***integrase*** , and a likely immunity gene contained all the
genetic information for faithful integration of a nonreplicative plasmid
into the ***attB*** site. A deletion within the int gene led to the
loss of integration proficiency. A number of spontaneous deletions were
observed in plasmids containing the 2.4-kb phage DNA segment. The
deletion

sites were localized to the tRNA side of the identity region and to phage
or vector DNA with 3- to 6-bp-long repeats from the border region. A
similar type of deletion was previously observed in a spontaneous phage
mutant.

L13 ANSWER 3 OF 130 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.

ACCESSION NUMBER: 1997:453335 BIOSIS

DOCUMENT NUMBER: PREV199799752538

TITLE: Integration specificities of two lambdoid phages (21 and
e14) that insert at the same ***attB*** site.

AUTHOR(S): Wang, Hui; Yang, Chung-Hui; Lee, Grace; Chang,
Felicia;

Wilson, Hilary; Del Campillo-Campbell, Alice; Campbell,
Allan (1)

CORPORATE SOURCE: (1) Dep. Biol. Sci., Stanford Univ., Stanford, CA
94305 USA

SOURCE: Journal of Bacteriology, (1997) Vol. 179, No. 18, pp.
5705-5711.

ISSN: 0021-9193.

DOCUMENT TYPE: Article

LANGUAGE: English

AB It was shown previously that phage 21 and the defective element e14
integrate at the same site within the icd gene of Escherichia coli K-12
but that 21 ***integrase*** and excisionase excise e14 in vivo very
infrequently compared to excision of 21. We show here that the reverse is
also true: e14 excises itself much better than it excises an adjacent 21
prophage. In vitro ***integrase*** assays with various ***attP***
substrates delimit the minimal ***attP*** site as somewhere between
366 and 418 bp, where the outer limits would include the outermost
repeated dodecamers suggested as arm recognition sites by S. J. Schneider
(Ph.D. dissertation, Stanford University, Stanford, Calif., 1992). We
speculate that the reason 21 ***attP*** is larger than lambda
attP (240 bp) is because it must include a 209-bp sequence
homologous to the 3' end of the icd transcript in order to allow icd
expression in lysogens. Alteration of portions of 21 ***attP*** to
their e14 counterparts shows that 21 requires both the arm site and core
site sequences of 21 but that replacements by e14 sequences function in
some positions. Consistent with Schneider's in vivo results, and like all
other known integrases from lambdoid phages, 21 requires integration host
factor for activity.